{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["icotinib"]],"indication":"stage II-IIIA EGFR-mutated lung adenocarcinoma","name":"ICWIP","nct_id":"NCT02125240","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=icwip-nct02125240. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ICWIP","arms":[{"description":"125 mg three times daily (375 mg per day) by mouth","label":"Icotinib","type":"EXPERIMENTAL"},{"description":"1 tablet three times daily by mouth","label":"Placebo","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2021-07","type":"ESTIMATED"},"conditions":["EGFR Positive Non-small Cell Lung Cancer","Adenocarcinoma"],"enrollment":{"count":124,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Icotinib","otherNames":["BPI-2009","Conmana"],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2018-07-16","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","official_title":"Icotinib as an Adjuvant Therapy for Stage II-IIIA Adenocarcinoma With EGFR Mutation: A Placebo-controlled, Randomized, Double-blind, Phase III Study","overall_status":"UNKNOWN","phases":["PHASE3"],"primary_completion_date":{"date":"2018-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease-free survival","timeFrame":"36 months"}],"references":[{"citation":"Liu YT, Tang L, Han XH, Song ZY, Liu DR, Cheng G, Xiao WH, Zhang SC, Hu Y, Zhang L, Liu JF, Wang J, Dong GL, Shi YK. Three-year adjuvant treatment of icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma (ICWIP): a randomized, double-blind, placebo-controlled phase 3 trial. Signal Transduct Target Ther. 2026 Aug 28;11(1):354. doi: 10.1038/s41392-026-02994-w.","pmid":"42660909","type":"DERIVED"},{"citation":"Liu YT, Hao XZ, Liu DR, Cheng G, Zhang SC, Xiao WH, Hu Y, Liu JF, He M, Ding CM, Zhang L, Wang J, Li H, Dong GL, Zhi XY, Li J, Shi YK. Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial. Cancer Manag Res. 2020 Jun 17;12:4633-4643. doi: 10.2147/CMAR.S240275. eCollection 2020.","pmid":"32606956","type":"DERIVED"}],"start_date":{"date":"2014-09"},"study_type":"INTERVENTIONAL","title":"Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma","url":"https://clinicaltrials.gov/study/NCT02125240"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/icwip-nct02125240"}